2005 Stock Overview An investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
SSY Group Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for SSY Group Historical stock prices Current Share Price HK$3.55 52 Week High HK$5.20 52 Week Low HK$3.26 Beta 0.62 1 Month Change -0.28% 3 Month Change -17.44% 1 Year Change -28.14% 3 Year Change -11.69% 5 Year Change -44.53% Change since IPO 36.02%
Recent News & Updates
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05 See more updates
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14
Investor sentiment improves as stock rises 18% Oct 02
Chairman & CEO recently bought HK$4.8m worth of stock Sep 25
SSY Group Limited Announces Update on Product Development Sep 09
Chairman & CEO recently bought HK$1.5m worth of stock Sep 04
SSY Group Limited Announces Update on Product Development Sep 02
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) Aug 31
First half dividend increased to HK$0.08 Aug 30 SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
SSY Group Limited Announces Update on Product Development Aug 07
Investor sentiment deteriorates as stock falls 16% Jul 29
SSY Group Limited Announces Update on Product Development Jul 23
SSY Group Limited Announces Update on Product Development Jul 16
SSY Group Limited Announces Update on Product Development Jun 29
SSY Group Limited Announces Update on Product Development Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jun 18
SSY Group Limited Announces Update on Product Development Jun 08 SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China
SSY Group Limited Announces Update on Product Development May 29
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China May 28
Upcoming dividend of HK$0.10 per share May 14
SSY Group Limited Provides Update on Product Development Apr 03
Chairman & CEO recently bought HK$2.5m worth of stock Mar 29
SSY Group Limited, Annual General Meeting, May 17, 2024 Mar 28
Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022) Mar 28
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 Mar 27
SSY Group Limited Announces Update on Product Development Mar 21
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China Mar 02
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market Mar 01
SSY Group Limited Receives Approval for Gliclazide Tablet Feb 28
SSY Group Limited Provides Update on Product Development Feb 24
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China Feb 19
SSY Group Limited Announces Update on Product Development Jan 31
SSY Group Limited Provides Update on Product Development Jan 24 SSY Group Limited Appoints Liu Wenjun as Non-Executive Director
Ssy Group Limited Provides Update on Product Development Jan 17
SSY Group Limited Announces Update on Product Development Jan 10
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jan 05
SSY Group Limited Provides Update on Product Development Dec 27
Chairman & CEO recently bought HK$4.7m worth of stock Dec 06
SSY Group Limited Announces Update on Product Development Dec 01
SSY Group Limited Announces Update on Product Development Nov 23
SSY Group Limited Announces Update on Product Development Nov 10
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 Nov 09
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 Nov 02
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection Nov 01
SSY Group Limited Announces Update on Product Development Oct 31
SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China Oct 27
SSY Group Limited Provides Update on Product Development Oct 26
SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China Oct 18
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China Oct 12
SSY Group Limited Announces Update on Product Development Oct 10
SSY Group Limited Announces Update on Product Development Sep 16
Upcoming dividend of HK$0.07 per share at 3.5% yield Sep 07
SSY Group Limited Announces Update on Product Development Sep 05
SSY Group Limited Provides Update on Product Development Sep 02
First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022) Aug 30
Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023 Aug 30
SSY Group Limited Announces Update on Product Development Aug 24
SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China Jul 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension Jul 14
Chairman & CEO recently bought HK$8.3m worth of stock Jul 08
SSY Group Limited Provides Update on Product Development Jul 07
SSY Group Limited Announces Update on Product Development Jun 30
SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China Jun 14
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection Jun 03
SSY Group Limited Announces Update on Product Development May 31
SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee May 20
Upcoming dividend of HK$0.08 per share at 2.8% yield May 16
SSY Group Limited Announces Update on Product Development May 13
SSY Group Limited Announces Update on Product Development May 12
Chairman & CEO recently bought HK$4.9m worth of stock May 10
SSY Group Limited Announces Update on Product Development May 09
Chairman & CEO recently bought HK$2.1m worth of stock Mar 30
Full year 2022 earnings released: EPS: HK$0.38 (vs HK$0.26 in FY 2021) Mar 29
Now 21% undervalued Mar 14
SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China Feb 07
SSY Group Limited Updates on Product Development Jan 31
SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market Jan 20
SSY Group Limited Obtains Approvals for Drug Production and Registration for Felodipine Sustained-Release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China Jan 06
Investor sentiment improved over the past week Jan 04
SSY Group Limited Announces Appointment of Jiang Guangce as an Independent Non-Executive Director and Member of Audit Committee, Nomination Committee and Remuneration Committee, with Effect from 1 January 2023 Dec 29
Less than half of directors are independent Nov 16
SSY Group Limited Obtains the Approval for Drug Production and Registration for Azithromycin Tablets (0.25G) from the National Medical Products Administration of China, Being Under Type 4 Chemical Drug and Regarded as Passing the Consistency Evaluation Nov 15
SSY Group Limited Obtains the Approval for Drug Productions from the National Medical Products Administration of China Oct 11 Shareholder Returns 2005 HK Pharmaceuticals HK Market 7D 2.9% 0.2% 1.1% 1Y -28.1% -9.6% 17.6%
See full shareholder returns
Return vs Market: 2005 underperformed the Hong Kong Market which returned 17.6% over the past year.
Price Volatility Is 2005's price volatile compared to industry and market? 2005 volatility 2005 Average Weekly Movement 5.0% Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 8.5% 10% most volatile stocks in HK Market 17.8% 10% least volatile stocks in HK Market 3.9%
Stable Share Price: 2005 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2005's weekly volatility (5%) has been stable over the past year.
About the Company SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials.
Show more SSY Group Limited Fundamentals Summary How do SSY Group's earnings and revenue compare to its market cap? 2005 fundamental statistics Market cap HK$10.50b Earnings (TTM ) HK$1.37b Revenue (TTM ) HK$6.47b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2005 income statement (TTM ) Revenue HK$6.47b Cost of Revenue HK$2.95b Gross Profit HK$3.52b Other Expenses HK$2.15b Earnings HK$1.37b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.46 Gross Margin 54.39% Net Profit Margin 21.11% Debt/Equity Ratio 47.7%
How did 2005 perform over the long term?
See historical performance and comparison Dividends
5.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 04:29 End of Day Share Price 2024/12/30 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SSY Group Limited is covered by 23 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Derrick Sun BNP Paribas Securities (Asia) Milo Liu BOCOM International Securities Limited Ying Shao BofA Global Research
Show 20 more analysts 
